BRPI0919268A2 - aptâmero para ngf e uso deste - Google Patents

aptâmero para ngf e uso deste

Info

Publication number
BRPI0919268A2
BRPI0919268A2 BRPI0919268A BRPI0919268A BRPI0919268A2 BR PI0919268 A2 BRPI0919268 A2 BR PI0919268A2 BR PI0919268 A BRPI0919268 A BR PI0919268A BR PI0919268 A BRPI0919268 A BR PI0919268A BR PI0919268 A2 BRPI0919268 A2 BR PI0919268A2
Authority
BR
Brazil
Prior art keywords
aptitude
ngf
Prior art date
Application number
BRPI0919268A
Other languages
English (en)
Inventor
Hiramatsu Hisanao
Jin Ling
Fujiwara Masatoshi
Miyakawa Shin
Nakamura Yoshikazu
Original Assignee
Ribomic Inc
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc, Shionogi & Co filed Critical Ribomic Inc
Publication of BRPI0919268A2 publication Critical patent/BRPI0919268A2/pt
Publication of BRPI0919268A8 publication Critical patent/BRPI0919268A8/pt
Publication of BRPI0919268B1 publication Critical patent/BRPI0919268B1/pt
Publication of BRPI0919268B8 publication Critical patent/BRPI0919268B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0919268A 2008-09-24 2009-09-18 aptâmero que se liga ao ngf e medicamento BRPI0919268B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008244982 2008-09-24
JP2008-244982 2008-09-24
PCT/JP2009/066457 WO2010035725A1 (ja) 2008-09-24 2009-09-18 Ｎｇｆに対するアプタマー及びその使用

Publications (4)

Publication Number Publication Date
BRPI0919268A2 true BRPI0919268A2 (pt) 2017-11-07
BRPI0919268A8 BRPI0919268A8 (pt) 2018-02-06
BRPI0919268B1 BRPI0919268B1 (pt) 2021-01-12
BRPI0919268B8 BRPI0919268B8 (pt) 2021-05-25

Family

ID=42059724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919268A BRPI0919268B8 (pt) 2008-09-24 2009-09-18 aptâmero que se liga ao ngf e medicamento

Country Status (16)

Country Link
US (1) US10260070B2 (pt)
EP (1) EP2354225B1 (pt)
JP (1) JP5602020B2 (pt)
KR (1) KR101694559B1 (pt)
CN (1) CN102171339B (pt)
AU (1) AU2009297626B2 (pt)
BR (1) BRPI0919268B8 (pt)
CA (1) CA2738129C (pt)
DK (1) DK2354225T3 (pt)
ES (1) ES2543222T3 (pt)
HU (1) HUE026595T2 (pt)
IL (1) IL211929A0 (pt)
MX (1) MX2011003144A (pt)
RU (1) RU2011116175A (pt)
WO (1) WO2010035725A1 (pt)
ZA (1) ZA201102682B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2011109642A1 (en) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
AU2011230388B2 (en) * 2010-03-24 2016-09-08 Fujimoto Pharmaceutical Corporation Aptamer for NGF and use thereof
NZ602618A (en) * 2010-04-12 2013-12-20 Somalogic Inc Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
JP5696830B2 (ja) * 2010-04-27 2015-04-08 株式会社アップウェル Ｐａｒ−２活性化阻害物質
JP2012024026A (ja) * 2010-07-23 2012-02-09 Tdk Corp Ｓｍ菌特異的アプタマー、Ｓｍ菌増殖抑制剤及びＳｍ菌の検出方法
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
EP2762569B1 (en) 2011-09-28 2018-06-13 RIBOMIC Inc. Ngf aptamer and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ATE315101T1 (de) 1992-09-29 2006-02-15 Gilead Sciences Inc Nukleinsäureliganden und ihre herstellungsmethoden
EP0724647A4 (en) 1993-09-08 2003-09-17 Gilead Sciences Inc NUCLEIC ACIDS AS LIGANDS AND IMPROVED PRODUCTION METHODS
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US7638464B2 (en) * 1999-04-26 2009-12-29 Biocept, Inc. Three dimensional format biochips
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
US20030077251A1 (en) * 2001-05-23 2003-04-24 Nicolas Escriou Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050215506A1 (en) * 2001-12-20 2005-09-29 Bennett C F Modulation of tyrosinase expression
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
US7888497B2 (en) * 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US7592441B2 (en) * 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
ES2397715T3 (es) 2006-11-14 2013-03-08 Ribomic Inc Aptámero contra midkina y uso del mismo
JP5012135B2 (ja) 2007-03-28 2012-08-29 コニカミノルタアドバンストレイヤー株式会社 超深度画像生成装置
WO2010008001A1 (ja) 2008-07-14 2010-01-21 国立大学法人 東京大学 Ｉｌ－１７に対するアプタマー及びその使用

Also Published As

Publication number Publication date
US20110251266A1 (en) 2011-10-13
HUE026595T2 (hu) 2016-06-28
RU2011116175A (ru) 2012-10-27
BRPI0919268B1 (pt) 2021-01-12
WO2010035725A1 (ja) 2010-04-01
EP2354225A4 (en) 2012-03-21
JP5602020B2 (ja) 2014-10-08
CN102171339A (zh) 2011-08-31
BRPI0919268A8 (pt) 2018-02-06
DK2354225T3 (en) 2015-06-29
EP2354225A9 (en) 2012-06-27
AU2009297626B2 (en) 2016-01-14
BRPI0919268B8 (pt) 2021-05-25
AU2009297626A2 (en) 2011-05-19
EP2354225B1 (en) 2015-04-22
ES2543222T3 (es) 2015-08-17
KR101694559B1 (ko) 2017-01-09
CN102171339B (zh) 2017-06-09
JPWO2010035725A1 (ja) 2012-02-23
ZA201102682B (en) 2012-06-27
CA2738129C (en) 2017-11-14
IL211929A0 (en) 2011-06-30
US10260070B2 (en) 2019-04-16
MX2011003144A (es) 2011-05-19
AU2009297626A1 (en) 2010-04-01
EP2354225A1 (en) 2011-08-10
KR20110059888A (ko) 2011-06-07
CA2738129A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI1010859A2 (pt) aptâmero para quimase, e uso do mesmo
BRPI0820457A2 (pt) Fluidos de ruptura e métodos de uso dos mesmos
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
CO6821883A2 (es) Nuevos moduladores y métodos para su uso
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI0717638A2 (pt) Anticorpors e imunoconjugados e usos para os mesmos
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI0914007A2 (pt) anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0921320A2 (pt) composições de anticorpo estáveis e métodos para estabilizar os mesmos
BR112013010272A2 (pt) métodos analíticos e arranjos para uso nos mesmos
BRPI0813105A2 (pt) Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BRPI0921087A2 (pt) válvula para utilização universal e diversas finalidades
BR112013006868A2 (pt) aparelho espaçador interespinhoso para fixação e métodos de uso
BRPI1011529A2 (pt) combinações de herbicidas à base de carbamoil triazolinona e métodos de uso
BRPI0915391A2 (pt) copolímero para estabilização de xisto e método de uso

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP)

B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP) , FUJIMOTO PHARMACEUTICAL CORPOR

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.